Cilostazol 73963-72-1

簡要描述：Cilostazol 73963-72-1
儲存/保存方法
Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

產(chǎn)品型號：abs47027080
廠商性質(zhì)：生產(chǎn)廠家
更新時間：2025-11-25
訪問量：1046

產(chǎn)品咨詢聯(lián)系我們

產(chǎn)品分類

Product Category

生化試劑

其它生化試劑植物提取物碳水化合物生物緩沖劑熒光探針與染料表面活性劑酶&輔酶&酶底物蛋白質(zhì)組學動植物激素小分子化合物生化檢測試劑盒逆行示蹤劑抗生素核苷&核苷酸多肽

查看全部

相關(guān)文章

詳細介紹

品牌	absin	CAS	73963-72-1
分子式	C20H27N5O2	純度	99%
分子量	369.46	貨號	abs47027080
規(guī)格	10mg	供貨周期	現(xiàn)貨
主要用途	used in the alleviation of the symptom o	應(yīng)用領(lǐng)域	化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合

Cilostazol 73963-72-1

產(chǎn)品描述
描述	Cilostazol is a medication used in the alleviation of the symptom of intermittent claudication in individuals with peripheral vascular disease. It is manufactured by Otsuka Pharmaceutical Co. under the trade name Pletal. Although drugs similar to cilostazol have increased the risk of death in patients with congestive heart failure, studies of significant size have not addressed people without the disease.
純度	99%
儲存/保存方法	Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.
基本信息
別名	西luo他唑; OPC 13013
外觀	off-white solid
可溶性/溶解性	DMSO : 50 mg/mL (135.33 mM; Need ultrasonic)
生物活性
靶點	PDE3
In vitro(體外研究)	Cilostazol (OPC-13013) is a 2-oxo-quinoline derivative with antithrombotic, vasodilator, antimitogenic and cardiotonic properties. The vasodilatory and antiplatelet actions of cilostazol are due mainly to the inhibition of phosphodiesterase 3 (PDE3) and subsequent elevation of intracellular cAMP levels. Cilostazol inhibits platelet aggregation. Cilostazol also possesses the ability to inhibit adenosine uptake. Elevation of interstitial adenosine by cilostazol in the heart is shown to reduce increases in cAMP caused by the PDE3-inhibitory action of cilostazol, thus attenuating the cardiotonic effects. Cilostazol is reported to inhibit smooth muscle cell proliferation. Cilostazol relaxes vascular smooth muscle and causes vasodilatation. Cilostazol inhibits the cytokine-induced expression of monocyte chemoattractant protein-1 (MCP-1). Cilostazol reduced plasma triglycerides and raised plasma HDL-cholesterol .
In vivo(體內(nèi)研究)	Cilostazol (clinically used doses; p.o.; for 2 weeks) could alleviate CCl4 -induced hepatic fibrogenesis in vivo, presumably due to its direct effect to suppress HSC activation. Cilostazol (intraperitoneal injection; 10 mg/kg; 7 consecutive days after ischemia) attenuates neurological dysfunctions, brain atrophy and infarct volume, and inhibits astrocyte proliferation/glial scar formation and accelerated the angiogenesis in the ischemic boundary zone 7 and 28 days after ischemia.

研究領(lǐng)域
研究領(lǐng)域	Signal TransductionMetabolism Drug DiscoverySmall Molecule DrugLead Compound Discovery

Cilostazol 73963-72-1溫馨提示：本產(chǎn)品僅作科研實驗使用，不支持臨床等研究

產(chǎn)品咨詢

留言框

產(chǎn)品：
您的單位：
您的姓名：
聯(lián)系電話：
常用郵箱：
省份：
詳細地址：
補充說明：
驗證碼：

請輸入計算結(jié)果（填寫阿拉伯數(shù)字），如：三加四=7

上一篇：abs47027079Berberine hydrochloride 633-65-8
下一篇：abs47027081Loxoprofen 68767-14-6

Cilostazol 73963-72-1

留言框

產(chǎn)品：

您的單位：

您的姓名：

聯(lián)系電話：

常用郵箱：

省份：

詳細地址：

補充說明：

驗證碼：